What is the recommended evaluation and treatment plan for bilateral hip inflammatory arthritis?

Bilateral Hip Inflammatory Arthritis: Evaluation and Treatment

For bilateral hip inflammatory arthritis, begin with NSAIDs as first-line therapy, advance to TNF inhibitors if disease remains active despite NSAIDs, and strongly consider total hip arthroplasty for advanced hip arthritis with refractory pain and disability.

Initial Evaluation

The diagnostic workup must distinguish inflammatory arthritis from osteoarthritis and identify the specific inflammatory etiology:

Laboratory Assessment:

• Complete blood count
• C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) to document inflammation 1
• Blood cultures if septic arthritis suspected
• Consider HLA-B27 if spondyloarthritis suspected

Imaging Protocol:

• Plain radiographs remain essential for initial evaluation 1
• Ultrasound should be performed to detect early inflammatory changes and joint effusion, particularly valuable when clinical examination is difficult 1, 2
• MRI is helpful for detecting early arthritis when radiographs are unrevealing 1

Joint Aspiration:

• Attempt in all cases, especially monoarthritis
• Synovial fluid analysis: white cell count, differential, crystal examination, Gram stain and cultures 1

Critical Pitfall: Routine hip ultrasound detects pathology in 33% of inflammatory arthritis patients, with 22% occurring in clinically and radiologically asymptomatic patients 2. Do not rely solely on symptoms or plain films.

Treatment Algorithm

Stage 1: Active Disease - Initial Management

Non-Pharmacological (Mandatory Core Interventions):

• Physical therapy - strongly recommended 3, 4
• Regular individualized exercise regimen including strengthening exercises for quadriceps and hip girdle muscles 5
• Patient education about disease nature, causes, and prognosis 5
• Weight reduction if overweight/obese 5
• Walking aids and assistive devices as needed 5

Pharmacological - First Line:

• NSAIDs at maximum dose as first-line drug treatment, taking risks and benefits into account 3, 4
• For patients responding well to NSAIDs, continuous use is preferred over on-demand dosing if symptomatic 4, 6
• In patients with GI risk: non-selective NSAIDs plus gastroprotective agent OR selective COX-2 inhibitor 7

Important Caveat: Do NOT use systemic glucocorticoids for axial disease 3. However, intra-articular steroid injections (ultrasound or x-ray guided) may be considered for flares unresponsive to NSAIDs 7, 4.

Stage 2: Persistent Active Disease Despite NSAIDs

Biologic Therapy:

• TNF inhibitors should be used when activity persists despite NSAID treatment 3
• Current practice is to start with TNFi therapy 4
• No particular TNFi is preferred EXCEPT:
  • Concomitant inflammatory bowel disease: use TNFi monoclonal antibodies 3, 6
  • Recurrent iritis: use TNFi monoclonal antibodies 3, 6

If TNFi Fails:

• Switch to another TNFi OR IL-17 inhibitor 4

What NOT to Use:

• Do NOT use conventional synthetic DMARDs (methotrexate, leflunomide) for purely axial disease 3, 4
• Sulfasalazine may be considered ONLY if peripheral arthritis is present 4
• Do NOT co-treat TNFi with low-dose methotrexate 6

Stage 3: Advanced Hip Arthritis

Surgical Intervention:

• Total hip arthroplasty is strongly recommended for patients with advanced hip arthritis who have refractory pain and disability 3
• Consider hip arthroplasty independent of age in patients with radiographic evidence of structural damage 7, 4
• In young adults with symptomatic disease and dysplasia or varus/valgus deformity, consider osteotomy and joint-preserving procedures 7

Bilateral Hip and Knee Involvement:

• When multiple joints require replacement, replace hips before knees 8
• Early surgical consultation is critical before all joints are irreparably destroyed and patient becomes non-ambulant 9
• Staged procedures (one joint at a time) considerably reduce stress and complications compared to simultaneous procedures 9

Disease Monitoring

Regular Assessment Should Include:

• Validated disease activity measures (e.g., ASDAS) 6
• CRP or ESR monitoring at regular intervals 6
• Patient-reported outcomes
• Clinical examination for joint status, mobility, and strength 5

Frequency: Individualized based on symptoms, severity, and treatment 4

Special Considerations

Ankylosed Joints:

• Patients with ankylosed joints have significantly lower ROM values post-arthroplasty but can still achieve meaningful functional improvement 10
• Higher complication rates (periprosthetic infection, joint stiffness) in patients with ankylosed joints 10

Spinal Involvement:

• If significant change in disease course occurs, consider causes other than inflammation (e.g., spinal fracture) and perform appropriate imaging 4
• In patients with spinal fusion or advanced spinal osteoporosis, strongly recommend AGAINST spinal manipulation 6

Smoking Cessation:

• Strongly encourage patients to stop smoking 4

This algorithmic approach prioritizes early aggressive treatment to prevent joint destruction while reserving arthroplasty for advanced disease, ultimately optimizing long-term function and quality of life.